Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
James Marken Insider Profile
11 Followers
James Marken, SVP OPS & PROD DEV at ANI Pharmaceuticals, holds 116.01K shares in ANI Pharmaceuticals (Ticker: ANIP).
James Marken ANI Pharmaceuticals (ANIP)SVP OPS & PROD DEV
ANI Pharmaceuticals (ANIP)
SVP OPS & PROD DEV
Ranked #63,351 out of 98,564 Corporate Insiders
Profitable Transactions
4 out of 9 Profitable Transactions
Average Return
-5.50%
Average return per transaction
Time Frame
Compare to
Insider Roles
SVP OPS & PROD DEV
Roles that James Marken holds in companies
Most Profitable Insider Trade
Stock:
Rating:Informative Sell
Date:May 15, 2019 - May 15, 2020
Return:+55.10%
The most profitable trade made by James Marken
James Marken's Trading History
List of latest transactions for each holding click on a transaction to see James Marken's performance on stock
You May Also Like
James Marken insider profile FAQ
What is the percentage of profitable transactions made by James Marken?
The percentage of profitable transactions made by James Marken is 44%.
What is the average return per transaction made by James Marken?
The average return per transaction made by James Marken is -5.50%.
What stocks does James Marken hold?
James Marken holds: ANIP stocks.
What was James Marken’s latest transaction?
James Marken latest transaction was an Uninformative Sell of $187.42K.
What was James Marken's most profitable transaction?
James Marken’s most profitable transaction was an Informative Sell of ANIP stock on May 15, 2019. The return on the trade was 55.10%.
What is James Marken's role in ANI Pharmaceuticals?
James Marken's role in ANI Pharmaceuticals is SVP OPS & PROD DEV.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.